New drug could keep lymphoma at bay in hepatitis b patients
NCT ID NCT07493109
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial is testing whether the drug chidamide can help prevent diffuse large B-cell lymphoma from returning in patients who also have hepatitis B. Participants must have achieved complete remission after initial chemotherapy (R-CHOP). They will take chidamide twice a week along with standard antiviral medication for hepatitis B. The study aims to see if this maintenance therapy improves how long patients stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chidamide (also called Tucidinostat) and Entecavir
What this could lead to
If successful, this could provide a new maintenance treatment option to help keep lymphoma in remission longer for patients with hepatitis B.
What could go wrong
This is a Phase 3 trial, but it is still recruiting and results are not yet available. Chidamide may cause side effects, and the benefit over current monitoring alone is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••